Best Peptides for Men: What the Male Community Actually Uses, by Goal (2026)

There is no single "best peptide for men," because men use peptides for very different goals - muscle and lean mass, fat loss, recovery, libido, and GH-driven anti-aging - and the right pick depends on your goal first. The peptide men reach for most overall is the CJC-1295/ipamorelin stack, followed by BPC-157 for recovery and MK-677 for GH support, but the single most important thing almost every "peptides for men" list gets wrong is the testosterone question: most peptides act on the growth-hormone axis and do not raise testosterone, and low testosterone itself is a TRT decision, not a peptide one. This page answers the real question two ways at once - what the male community actually uses, by goal, and where to go next for the deep ranking on each goal.

Most "peptides for men" content is a thin protocol dump or a vague stack listicle that quietly implies peptides will fix low T. We do it differently, and we do it honestly. The headline below comes from first-party usage data - what ~4,200 men in the ProtocolPlus community actually track, segmented by goal - and the rest of this page is a clean routing map: each goal gets a short community-pick teaser and a link to the dedicated best-for page that owns it, plus a link up to each compound's hub for the science. This is an orientation hub. It tells you which goal points where; it does not re-rank a goal that a sibling page already owns.

Key Takeaways

• What men use (not an efficacy ranking): across ~4,200 men in the ProtocolPlus community, the top picks are CJC-1295/ipamorelin (22%), BPC-157 (16%), and MK-677 (12%), then tesamorelin (8%), IGF-1 LR3 (8%), PT-141 (8%), GLP-1 fat-loss drugs (8%), TB-500 (7%), sermorelin (7%), and a small other (4%) bucket (ProtocolPlus app data).
• Choose by goal first, then follow the route. Muscle and lean mass point to CJC-1295/ipamorelin and IGF-1 LR3; fat loss points to the GLP-1 drugs and tesamorelin; recovery and injury point to BPC-157 and TB-500; libido points to PT-141; GH support and anti-aging point to CJC-1295/ipamorelin, sermorelin, or MK-677.
• The testosterone honesty most lists skip: most peptides men use act on the GH axis (or for tissue repair), and almost none raise testosterone. If your real goal is higher testosterone, that is a TRT decision, not a peptide one - see our TRT guide.
• Only a few are FDA-approved, and not for these uses in men. PT-141 (Vyleesi) is approved for premenopausal women (male use off-label), tesamorelin (Egrifta) for HIV lipodystrophy, and the GLP-1 drugs for weight. The popular GH-axis muscle peptides are research-grade.
• Fertility and HPTA preservation are a different lane. Gonadorelin and kisspeptin are used to protect the testosterone axis and fertility on or after hormone therapy - they route to the TRT/PCT conversation, not to a testosterone-raising peptide.
• This is a routing hub. Each goal links to the page that owns it. Want FDA-approved-only, or muscle-only, or the honest low-T answer? Filter the selector above.

What peptides do men in the ProtocolPlus community actually use?

Across ~4,200 men in the ProtocolPlus community, the CJC-1295/ipamorelin stack is the most-tracked (22%), followed by BPC-157 (16%) and MK-677 (12%) - so growth-hormone support and recovery account for most of what men reach for, not testosterone. This is a usage ranking from our own app data, segmented for men, not a clinical verdict on what works best.

The pattern tells the real story of male peptide use. The leaders are GH-axis tools (CJC-1295/ipamorelin, MK-677, sermorelin, tesamorelin) and repair peptides (BPC-157, TB-500), with a fat-loss slice (GLP-1, tesamorelin) and a libido slice (PT-141). After the leaders, usage spreads into a goal-diverse tail: tesamorelin (8%) and IGF-1 LR3 (8%) for visceral fat and hypertrophy, PT-141 (8%) for sexual function, the GLP-1 fat-loss drugs (8%), TB-500 (7%), sermorelin (7%), and a 4% "other" bucket spanning gonadorelin, kisspeptin, epitalon, and thymosin alpha-1.

[UNIQUE INSIGHT] Here is the thing the chart makes obvious that "peptides for men" lists hide: testosterone is almost absent. Men come to peptides hoping for a higher-testosterone, more-masculine result, but what they actually use overwhelmingly acts on the GH axis or on tissue repair, and none of it raises testosterone. The one compound that does - testosterone itself, via TRT - is not a peptide, so it is not even in this ranking. That gap between what men want (more T) and what peptides do (GH-axis and repair) is the single most useful insight on this page, and it is why we route low-T questions straight to the TRT cluster instead of pretending a peptide will fix them.

These shares come only from our male-community usage dataset and describe behavior, not efficacy. A compound can be widely used and weakly evidenced at the same time - IGF-1 LR3 is exactly that case, popular in bodybuilding circles with no human physique trials. Read this chart as "what men in the community reach for," then follow each goal to the page that ranks it properly.

Citation capsule. Among ~4,200 men in the ProtocolPlus community, the most-tracked compounds were CJC-1295/ipamorelin (22%, 924 users), BPC-157 (16%, 672), MK-677 (12%, 504), tesamorelin (8%, 336), IGF-1 LR3 (8%, 336), PT-141 (8%, 336), GLP-1 fat-loss drugs (8%, 336), TB-500 (7%, 294), and sermorelin (7%, 294). Most act on the growth-hormone axis; none raise testosterone. This is first-party usage data reflecting what men use, not a clinical efficacy ranking. Source: ProtocolPlus app data (goals/men.json), 2026.

Which peptide fits which goal - the men's decision map

The most useful way for a man to choose is by his actual goal: muscle and lean mass route to CJC-1295/ipamorelin and IGF-1 LR3, fat loss routes to the GLP-1 drugs and tesamorelin, recovery and injury route to BPC-157 and TB-500, libido routes to PT-141, GH support and anti-aging route to CJC-1295/ipamorelin or sermorelin or MK-677, and low testosterone routes to TRT - not a peptide. This goal-first routing is the signature of this page, and it is the orientation, not a deep ranking.

This is the map most "peptides for men" lists never build. They pile compounds into one stack with no goal logic, so a man cannot tell which one is even relevant to his goal, and they quietly imply the whole list will make him more masculine. Each card below names the goal, the peptide men reach for, the honest reason they pick it, and - crucially - the dedicated page that owns the full ranking for that goal. The deep, single-goal rankings live on their own pages, not here.

The routing diagram below puts the same logic on one map, so you can see at a glance which goal points to which dedicated page - and where the central TRT bridge sits for the low-testosterone question. The selector quiz at the top runs this interactively: choosing muscle surfaces CJC-1295/ipamorelin and routes to the muscle page, choosing fat loss routes to the weight-loss page, and answering yes to "are you trying to raise testosterone?" surfaces the low-T routing band straight to TRT.

The routing table below puts the same map in detail, adding the route, the FDA status, the axis each compound acts on, and where to go for the full ranking on that goal.

Do peptides raise testosterone in men?

No - this is the single biggest misconception, and the honest answer is that almost none of the peptides men use raise testosterone; most act on the growth-hormone axis or on tissue repair, and the one thing that reliably raises testosterone is testosterone itself, via TRT, which is not a peptide. If higher testosterone is your real goal, you are looking at a TRT decision, not a peptide one.

This is where competitors mislead men most, so it deserves a clear, mechanism-level answer. The GH-axis peptides (CJC-1295, ipamorelin, sermorelin, tesamorelin, MK-677, IGF-1 LR3) prompt your own pituitary to release growth hormone, or act downstream of it - they do not add or stimulate androgens, so they do not raise testosterone. Repair peptides (BPC-157, TB-500) work on tissue signaling, not sex hormones. PT-141 acts on a brain melanocortin desire pathway, not on the testosterone axis. None of these turn into testosterone or push your gonads to make more of it.

The cleanest way to hold this in your head is two separate axes. The growth-hormone axis runs hypothalamus to pituitary to GH and IGF-1, and almost every peptide men actually buy lives on this axis - it changes body composition, sleep, and recovery, but it never touches your sex hormones. The other axis is the hypothalamic-pituitary-gonadal axis, the HPG or HPTA axis, which runs GnRH to LH and FSH to the testes, and that is the only chain that ends in testosterone. A peptide has to act on the second axis to move testosterone at all, and the GH-axis crowd simply does not. That single distinction explains why a man can run CJC-1295/ipamorelin for a year, feel leaner and sleep better, and see his testosterone bloodwork barely move.

There is one more honest wrinkle men ask about: enclomiphene. It does raise testosterone in men by blocking estrogen feedback at the hypothalamus, which lifts LH and FSH and pushes the testes to make more of your own testosterone. But enclomiphene is a SERM, a small-molecule drug, not a peptide, so it is not on this list either, and it still belongs in the bloodwork-gated hormone conversation, not a self-directed peptide stack. So the rule holds with no real exception: if a compound reliably raises a man's testosterone, it is not a peptide, and it routes to the hormone clinic, not here.

[UNIQUE INSIGHT] There is one honest exception that proves the rule, and most lists either ignore it or overstate it: gonadorelin and kisspeptin act on the hypothalamic-pituitary-gonadal (HPTA) axis - they signal upstream of testosterone production, which is why they are used to preserve fertility and testicular function on or after hormone therapy, in post-cycle therapy contexts. But that is HPTA preservation, not a "testosterone booster" you take to feel more masculine. They belong in the TRT and PCT conversation under a clinician, not in a self-directed stack, and they route to the TRT cluster, not to a peptide-for-T claim. So the two-layer honest framing for men is: the peptides you actually use act on GH or repair and do not raise testosterone, and the few that touch the testosterone axis (gonadorelin, kisspeptin) are HPTA-preservation tools tied to TRT, not standalone T-boosters.

The visual below makes this concrete: it groups every candidate by the axis it acts on and shows, in one view, that not a single peptide here raises testosterone. For the actual low-testosterone decision - symptoms, bloodwork, whether TRT is right for you, and how peptides like gonadorelin fit around it - see the TRT guide.

Citation capsule. The peptides men commonly use do not raise testosterone. Growth-hormone-axis peptides (CJC-1295, ipamorelin, sermorelin, tesamorelin, MK-677, IGF-1 LR3) act on the GH axis; repair peptides (BPC-157, TB-500) act on tissue signaling; PT-141 acts on a brain melanocortin pathway. Only gonadorelin and kisspeptin act on the testosterone (HPTA) axis, and they are HPTA-preservation tools tied to TRT/PCT, not standalone testosterone boosters. Low testosterone is a TRT decision. Source: peptide pharmacology and FDA labeling (Egrifta/tesamorelin, Vyleesi/bremelanotide), 2010-2026.

What about male fertility and protecting the testicular axis?

For men who care about fertility, the relevant compounds are the ones that act on the testicular (HPTA) axis - gonadorelin, kisspeptin, and hCG - and their job is to keep your own LH and FSH signaling alive so the testes keep producing sperm and testosterone, not to "boost" anything. This is a TRT-and-fertility conversation, not a peptide-for-T one.

Here is the male-specific problem these compounds address. When a man goes on testosterone, the brain reads the high blood level and shuts down its own GnRH, LH, and FSH output, the testes go quiet, and fertility and testicular size can drop. Gonadorelin (a GnRH analog) and hCG (which mimics LH) are used to keep that signal pulsing so the testes stay active on therapy, and kisspeptin sits one step upstream as the switch that drives GnRH in the first place. None of this is a self-directed stack you run for gym goals - it is HPTA preservation managed alongside hormone therapy by a clinician who can read your bloodwork and a semen analysis.

The practical takeaway for men is simple. If your concern is staying fertile while on or after testosterone, that is a real, answerable question, but it is owned by the hormone side of the house, not by a GH-axis peptide. For the testicular-axis and fertility picture, see TRT and fertility, and for how hCG and gonadorelin fit specifically, see TRT and hCG. No peptide here is a fertility treatment on its own, and none of them raise testosterone.

Citation capsule. For male fertility, the compounds that matter act on the hypothalamic-pituitary-gonadal axis: gonadorelin (a GnRH analog) and hCG (an LH mimic) keep LH/FSH signaling and testicular function active during testosterone therapy, while kisspeptin drives GnRH upstream. These are HPTA-preservation tools managed by a clinician alongside hormone therapy and bloodwork, not standalone testosterone boosters or self-directed peptide stacks. Source: GnRH/gonadorelin/kisspeptin reproductive-endocrine literature and Endocrine Society testosterone guidance, 2013-2026.

Each candidate for men, briefly (with where to go deeper)

Here is each candidate in two-to-four sentences - enough to place it for a man's goal, with a link up to its full guide for the science and out to the page that ranks it. This page owns the "which goal points where" decision; the mechanism, dosing, and side-effect depth live on each compound's hub, and the deep single-goal ranking lives on the dedicated best-for page.

CJC-1295 and ipamorelin

The men's community's most-tracked stack overall, used together as growth-hormone-releasing peptides for lean mass, sleep, recovery, and body composition - acting on the GH axis, not testosterone. They are research-grade, not FDA-approved, with limited human outcome data. Full guides: CJC-1295 guide and ipamorelin guide; the muscle ranking lives on best peptides for muscle growth.

BPC-157

The community's go-to recovery and repair peptide for soft-tissue, tendon, and gut support, popular with active and lifting men. The evidence is largely animal data, it is research-grade and not FDA-approved, and tissue-growth-signaling warrants caution with any cancer concern. Full guide: BPC-157 complete guide; the recovery ranking: best peptides for recovery.

MK-677 (ibutamoren)

An oral growth-hormone secretagogue tracked by men for appetite, sleep, and lean mass - the "no needles" GH-axis option. It is investigational, not FDA-approved, and can raise appetite, blood glucose, and water retention; it does not raise testosterone. Full guide: MK-677 complete guide.

Tesamorelin

A GH-releasing hormone analog FDA-approved as Egrifta for HIV-associated visceral fat, tracked by men off-label for belly-fat reduction - the strongest-evidenced GH-axis fat-loss tool. Outside that approval it is off-label or research-grade. Full guide: tesamorelin guide; the fat-loss ranking: best peptides for weight loss.

IGF-1 LR3

A long-acting IGF-1 analog tracked by bodybuilding men for hypertrophy and nutrient partitioning, downstream of the GH axis. It is research-grade with no human physique trials, and its mitogenic profile warrants real caution where malignancy is a concern. A small high-risk fringe in this advanced lane also experiments with the potent GH-spiking secretagogue hexarelin and the myostatin inhibitor follistatin-344, both of which carry far worse evidence-to-risk profiles. Full guide: IGF-1 LR3 guide; the bodybuilding ranking: best peptides for bodybuilding.

PT-141 (bremelanotide)

A brain-pathway libido peptide that acts on melanocortin receptors, not hormones, tracked by men for sexual function and ED support. It is FDA-approved as Vyleesi for premenopausal women, so male use is off-label, and it can raise blood pressure and cause nausea. Full guide: PT-141 complete guide; the libido ranking: best peptides for libido.

TB-500

A thymosin beta-4 fragment tracked by men for soft-tissue and tendon recovery, usually stacked with BPC-157. The evidence is animal data only, it is research-grade and not FDA-approved. Full guide: TB-500 guide; the injury ranking: best peptides for injury healing.

Sermorelin

A GH-releasing hormone analog tracked by men for GH support, sleep, and anti-aging body composition - a gentler GH-axis option, previously marketed as Geref and now compounded or research-grade. It does not raise testosterone. Full guide: sermorelin guide; the anti-aging ranking: best peptides for longevity.

GLP-1 fat-loss drugs (semaglutide, tirzepatide)

The FDA-approved GLP-1/GIP weight-loss drugs (Wegovy and Zepbound) and the most evidence-backed fat-loss option, used by men cutting body fat. They get one orientation sentence here because the full ranking, trial numbers, and depth live on the weight-loss page: best peptides for weight loss.

Gonadorelin and kisspeptin (HPTA / fertility - route to TRT/PCT)

The two compounds that actually touch the testosterone axis, used to preserve fertility and testicular function on or after hormone therapy. They are HPTA-preservation tools tied to the TRT and post-cycle conversation, not standalone testosterone boosters, and they currently route to the TRT cluster rather than a dedicated hub: TRT guide and the TRT/PCT cluster.

TRT (testosterone - the male bridge, not a peptide)

Testosterone replacement is the one thing that reliably raises testosterone, and it is not a peptide - it is a Schedule-III, clinic-managed, bloodwork-gated therapy. If your real goal is more testosterone, this is the decision to make, and peptides are not a substitute. Start here: the TRT guide and cluster.

What the male community uses is not what is proven best

Treat the usage ranking as a popularity signal shaped by goal, availability, and gym-culture hype - not as evidence of what works best or safest for men. The clearest proof is IGF-1 LR3, which has no human physique trials yet pulls a real bodybuilding cohort simply because it is part of advanced stacks.

Three honest framings sit on top of every number on this page. First, evidence tier rarely matches usage: the GH-axis muscle and recovery peptides men reach for most are largely research-grade with animal or limited human data, while the few FDA-approved options (the GLP-1 drugs, tesamorelin for its narrow indication, PT-141 for women) are not the most-used. Second, most peptides do not do what men hope - they support GH and recovery, they do not raise testosterone, and chasing a "more masculine" result with a GH-axis peptide is a category error. Third, research-grade vials carry quality risk - unknown potency, purity, and sterility - that no usage statistic captures. For grounded expectations, see peptides before and after, and before sourcing anything research-grade, read how to vet peptide quality and are peptides legal.

Our take: The most useful way to read this page is as two layers. The usage chart tells you what real men are doing; the routing map and the testosterone visual tell you what each peptide actually does and where the real decision lives. When what men want (more testosterone, a stronger body) and what peptides do (GH-axis support, repair) diverge - as they constantly do - trust the mechanism, not the marketing, and route the low-T question to TRT.

Does peptide choice change with age - your 20s, 40s, and 50s+?

Yes, honestly - the goal that brings a man to peptides shifts with age, and so does the right route: younger men skew toward muscle and recovery (GH-axis and repair peptides), while older men more often arrive with fat gain, flagging recovery, sleep, and the low-testosterone question that points to TRT. Matching the tool to the life stage matters as much as matching it to the goal.

This is the by-life-stage honesty most lists skip, and the shift is real enough to walk through decade by decade. In a man's 20s and 30s, peptide interest usually centers on muscle, lean mass, performance, and bouncing back from training and minor injuries - this is the GH-axis and repair lane (CJC-1295/ipamorelin, BPC-157, TB-500), and it is the stage where the testosterone question is least likely to be the real issue, because natural production is usually still strong. The honest move here is often "train, eat, and sleep first," and treat peptides as a small, optional lever, not the headline.

In the 40s, the picture changes. Natural GH output and recovery capacity have been drifting down for years, sleep gets lighter, fat creeps onto the midsection, and libido can dip - so men in this decade arrive with a blend of body-composition and recovery goals plus the first real "is my testosterone low?" question. This is exactly where the GH-axis-versus-testosterone confusion peaks. A GH secretagogue may help body composition and sleep, but if the underlying issue is genuinely low testosterone, no GH peptide fixes it.

From the 50s onward, the center of gravity shifts again toward longevity, lean-mass preservation, healthspan, and the low-testosterone conversation becomes far more common and more often clinically real. The right route for a 55-year-old is rarely "pick a peptide off a list" - it is bloodwork first, then a clinician-led decision that may or may not include TRT, with GH-axis or recovery peptides as a separate, goal-specific question. None of this is a dosing recommendation by age; doses are individualized and clinic-led, and we deliberately do not print them. The age-specific decision deepens on the pages that own each goal, especially the TRT guide for the low-testosterone picture and best peptides for longevity for the anti-aging route.

Our take: "Peptides for men" gets blurred with "testosterone for men" most often in the 40-plus crowd, and that blur leads straight to mismatched expectations. A GH-releasing or recovery peptide is not a treatment for low testosterone, and no peptide here replaces TRT where it is indicated. Get bloodwork, match the tool to the actual goal and life stage, and read the TRT guide if low T is the real question.

Who should be cautious, and the hard lines

Peptides are not for everyone, and the research-grade ones are not for anyone outside a clinician's oversight - and for men specifically, the most common mistake is self-treating a suspected low-testosterone problem with a peptide instead of getting it properly worked up. The GH-axis and research-grade compounds add unknown-risk on top of that.

A few hard lines worth stating for men. Anyone with active or recent cancer, or a strong concern about it, needs specialist input before any growth-signaling peptide (GH-axis peptides, IGF-1 LR3, BPC-157, TB-500), because anything that nudges growth or IGF-1 signaling is a particular caution there - IGF-1 LR3 most of all, given its mitogenic profile. MK-677 can raise blood glucose and is a caution for anyone with insulin resistance or diabetes. PT-141 can raise blood pressure and is not for men with uncontrolled hypertension or cardiovascular disease. The GLP-1 class carries its own contraindications, including a personal or family history of medullary thyroid carcinoma or MEN 2 (FDA Wegovy prescribing information, retrieved 2026-06-19). And if you suspect low testosterone, the responsible path is bloodwork and a clinician, not a self-directed peptide cycle - low T is a TRT decision (Endocrine Society, testosterone therapy clinical practice guideline, 2018, retrieved 2026-06-19). For the research-grade compounds, there is no validated safe-use protocol, so they belong under a clinician, not in a self-directed stack. Before sourcing anything research-grade, read how to vet peptide quality and are peptides legal.

What should a man actually monitor? For the GH-axis secretagogues, the two numbers that matter most are fasting glucose (and HbA1c) and IGF-1, because GH stimulation can nudge insulin resistance and push IGF-1 up - which is the same growth signaling that warrants the cancer caution above. Men who carry extra abdominal fat or have a family history of diabetes are exactly the ones who should not skip the glucose check. On the GLP-1 drugs, the watch items are GI tolerance, hydration, and any thyroid or pancreatic red flags. And underneath all of it, the honest expectation for men is patience: GH-axis changes in body composition and sleep show up over weeks to a few months, not days, and a research-grade vial of unknown potency may do far less than the label implies. This bloodwork-first discipline is the same backbone the hormone side runs on - if you are even considering the testosterone question, baseline labs are not optional.

How should a man actually start - the honest sequence

The right starting move for a man is not "pick a peptide," it is to define the goal, get baseline bloodwork, then let the goal and the labs decide whether a peptide, a GLP-1 drug, or a TRT conversation is even the answer. Order matters more than the specific compound, and this hub deliberately routes the specifics out.

Here is the sequence we think is honest, in plain order:

1. Name the real goal. Muscle, fat loss, recovery, libido, GH-driven anti-aging, or "I feel flat and tired and think my testosterone is low" - these point to completely different lanes, and the last one is a hormone question, not a peptide one.
2. Get baseline bloodwork. At minimum the labs that map to your goal: a full hormone panel if testosterone or libido is in play, plus fasting glucose, HbA1c, and IGF-1 if you are eyeing a GH-axis peptide. Baseline first means you can actually tell later whether anything changed.
3. Match the tool to the goal, then route out. Let the goal pick the lane, and follow this hub to the page that owns the deep ranking - muscle to muscle growth, fat loss to weight loss, recovery to recovery, libido to libido, anti-aging to longevity, and low testosterone to the TRT guide.
4. Track against the baseline. Re-check the same labs and your goal metrics after a defined window, and judge results against numbers, not vibes. If the goal was higher testosterone and the compound was a GH-axis peptide, the labs will tell you the honest truth: it did not move.

Notice this page never hands you a dose or a vial - that is on purpose. Doses come from real trials and a clinician, the deep ranking lives on the goal page that owns it, and the testosterone question lives with the hormone clinic. This hub's job is to get you into the right lane, honestly.

Frequently Asked Questions

The bottom line

If you came here for a single "best peptide for men," the honest answer is that it depends on your goal, and the most important thing to get right is what peptides actually do. Choose by goal first and follow the route: CJC-1295/ipamorelin and IGF-1 LR3 for muscle, the GLP-1 drugs and tesamorelin for fat loss, BPC-157 and TB-500 for recovery, PT-141 for libido, and CJC-1295/ipamorelin, sermorelin, or MK-677 for GH support and anti-aging. This page is the map; each goal links to the page that owns its full ranking.

The bigger, male-specific insight is the one most lists bury: almost no peptide raises testosterone. The compounds men use overwhelmingly act on the GH axis or on tissue repair, and if your real goal is higher testosterone, that is a TRT decision - a Schedule-III, clinic-managed therapy that is not a peptide at all. Gonadorelin and kisspeptin touch the testosterone axis only as HPTA-preservation tools tied to TRT and post-cycle therapy. The selector at the top narrows the field to your goal and constraints, but the final call belongs with a clinician who knows your history. From here, the natural next reads are the TRT guide, best peptides for muscle growth, and how to vet peptide quality.

Sources

• U.S. Food & Drug Administration. "Egrifta (tesamorelin for injection) - Prescribing Information" (approved for HIV-associated lipodystrophy/visceral adipose tissue). 2010-2014. Retrieved 2026-06-19. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022505s007lbl.pdf
• U.S. Food & Drug Administration. "FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women" (Vyleesi / bremelanotide / PT-141). 2019. Retrieved 2026-06-19. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hypoactive-sexual-desire-disorder-premenopausal-women
• U.S. Food & Drug Administration. "Wegovy (semaglutide) injection - Prescribing Information" (contraindications: MTC/MEN 2). 2021. Retrieved 2026-06-19. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
• Bhasin S, Brito JP, Cunningham GR, et al. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." Journal of Clinical Endocrinology & Metabolism, 2018. Retrieved 2026-06-19. https://academic.oup.com/jcem/article/103/5/1715/4939465
• Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157 in the treatment of soft-tissue and tendon healing (animal literature review)." Current Pharmaceutical Design / Journal of Physiology-Paris, 2010-2018. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/29879879/
• Sigalos JT, Pastuszak AW. "The Safety and Efficacy of Growth Hormone Secretagogues (CJC-1295, ipamorelin, sermorelin, MK-677/ibutamoren) - a review." Sexual Medicine Reviews, 2018. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/28705536/
• Millar RP, Newton CL. "Current and future applications of GnRH/gonadorelin and kisspeptin in reproductive and HPTA-axis medicine (review)." Molecular and Cellular Endocrinology / Nature Reviews Endocrinology, 2013-2022. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/23624157/
• ProtocolPlus. "Community goal-usage data: men" (goals/men.json). First-party app data, 2026. n ≈ 4,200 men. Usage signal, not a clinical efficacy ranking. TRT excluded as non-peptide.